Eculizumab-Aeeb: uses, dosing, side effects & brands
Eculizumab-Aeeb is a medicine sold in the U.S. under one brand, for paroxysmal hemoglobinuria, myasthenia gravis and atypical hemolytic uremic syndrome. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Paroxysmal Hemoglobinuria, Myasthenia Gravis and Atypical Hemolytic Uremic Syndrome
- Available as
- Injectable
- Sold as
- Bkemv
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
- Boxed warning
- Boxed warning
How eculizumab-aeeb is dosed
From the FDA label for Bkemv (application BLA761333). Other eculizumab-aeeb products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
For intravenous infusion only; recommended dosage for: PNH: ( 2.2 ) aHUS, gMG, and NMOSD in adults: ( 2.3 ) aHUS in pediatric patients: ( 2.4 ) 2.1 Recommended Vaccination and Prophylaxis for Meningococcal Infection Vaccinate patients against meningococcal infection (serogroups A, C, W, Y and B) according to current ACIP recommendations at least 2 weeks prior to initiation of BKEMV [see Warnings and Precautions (5.1) ] . If urgent BKEMV therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible. Healthcare providers who prescribe BKEMV must enroll in the BKEMV REMS [see Warnings and Precautions (5.2) ] . 2.2 Recommended Dosage for Adults – PNH The recommended dosage of BKEMV for the treatment of PNH in patients 18 years of age and older is administered as an intravenous infusion [see Dosage and Administration (2.7) ] as follows: 600 mg weekly for the first 4 weeks, followed by 900 mg for the fifth dose 1 week later, then 900 mg every 2 weeks thereafter. Administer BKEMV at the recommended dosage regimen time points, or within two days of these time points [see Warnings and Precautions (5.4)] . 2.3 Recommended Dosage for Adults – aHUS, gMG, and NMOSD The recommended dosage of BKEMV for the treatment of aHUS, gMG,…
Eculizumab-Aeeb side effects
The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Serious Meningococcal Infections [see Warnings and Precautions (5.1) ] Other Infections [see Warnings and Precautions (5.3) ] Monitoring Disease Manifestations after BKEMV Discontinuation [see Warnings and Precautions (5.4) ] Thrombosis Prevention and Management [see Warnings and Precautions (5.5) ] Infusion-Related Reactions [see Warnings and Precautions (5.6) ] The most frequently reported adverse reactions in the PNH randomized trial (≥ 10% overall and greater than placebo) are: headache, nasopharyngitis, back pain, and nausea. ( 6.1 ) The most frequently reported adverse reactions in aHUS single arm prospective trials (≥ 20%) are: headache, diarrhea, hypertension, upper respiratory infection, abdominal pain, vomiting, nasopharyngitis, anemia, cough, peripheral edema, nausea, urinary tract infections, pyrexia. ( 6.1 ) The most frequently reported adverse reaction in the gMG placebo-controlled clinical trial (≥ 10%) in adult patients is musculoskeletal pain. ( 6.1 ) The most frequently reported adverse reactions in the NMOSD placebo-controlled trial (≥ 10%) are: upper respiratory infection, nasopharyngitis, diarrhea, back pain, dizziness, influenza, arthralgia, pharyngitis, and contusion. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Amgen Medical Information…
Who shouldn’t take eculizumab-aeeb
BKEMV is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection [see Warnings and Precautions (5.1) ] . BKEMV is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection. ( 4 )
Eculizumab-Aeeb drug interactions
7.1 Plasmapheresis, Plasma Exchange, Fresh Frozen Plasma Infusion or IVIg Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of BKEMV [see Dosage and Administration (2.5) ] . 7.2 Neonatal Fc Receptor Blockers Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of BKEMV.
Every eculizumab-aeeb product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Bkemv.
Related calculators
Frequently asked questions
What is eculizumab-aeeb?
Bkemv (Eculizumab-Aeeb) is a medication used to treat Paroxysmal Hemoglobinuria, Myasthenia Gravis, Atypical Hemolytic Uremic Syndrome.
Can you take eculizumab-aeeb with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run eculizumab-aeeb against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does eculizumab-aeeb come in?
Across the brands we track, eculizumab-aeeb is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic eculizumab-aeeb?
We do not currently list a generic-labelled eculizumab-aeeb product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Eculizumab-Aeeb: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/eculizumab-aeeb
- MLA
- “Eculizumab-Aeeb: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/eculizumab-aeeb.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for eculizumab-aeeb on DailyMed (NIH) ↗ — including its boxed warning in full.